Inactive Instrument

Meridian Bioscience, Inc.

Equities

VIVO

US5895841014

Medical Equipment, Supplies & Distribution

Meridian Bioscience, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022

February 09, 2023 at 08:23 am EST

Meridian Bioscience, Inc. reported earnings results for the first quarter ended December 31, 2022. For the first quarter, the company reported sales was USD 56.9 million compared to USD 88.34 million a year ago. Net loss was USD 29.82 million compared to net income of USD 15.34 million a year ago.

Basic loss per share from continuing operations was USD 0.68 compared to basic earnings per share from continuing operations of USD 0.35 a year ago. Diluted loss per share from continuing operations was USD 0.68 compared to diluted earnings per share from continuing operations of USD 0.35 a year ago.

Latest news about Meridian Bioscience, Inc.

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits	Apr. 10	CI
Meridian Bioscience, Inc. announced that it has received KRW 128.772575398 billion in funding	Nov. 29	CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 128.772575393 billion in funding	Nov. 21	CI
Meridian Bioscience, Inc. announced that it has received KRW 258.225164381 billion in funding from Columbus Holding Company	23-07-27	CI
Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex	23-07-25	CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding	23-06-11	CI
Meridian Bioscience, Inc. Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay	23-04-19	CI
Meridian Bioscience, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-09	CI
SD Biosensor, SJL Partners Acquire Meridian Bioscience	23-01-31	MT
Meridian Bioscience, Inc.(NasdaqGM:VIVO) dropped from NASDAQ Composite Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Healthcare Equipment Select Industry Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Composite 1500	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Global BMI Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P TMI Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 1000	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600 Health Care	23-01-31	CI
SD BioSensor, Inc and SJL Partners completed the acquisition of Meridian Bioscience, Inc. from Impactive Capital LP, BlackRock, Inc., The Vanguard Group, Inc, Royce & Associates, LP and others.	23-01-30	CI
DoubleVerify Holdings to Replace Meridian Bioscience in S&P SmallCap 600	23-01-26	MT
Meridian Bioscience Says Closing Date of Pending Merger With SD Biosensor, Others Pushed Back to Jan. 31	22-12-12	MT
Meridian Bioscience Fiscal Q4 Adjusted EPS, Revenue Decline	22-11-22	MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 Revenue $65.7M	22-11-22	MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 EPS $0.20	22-11-22	MT
Meridian Bioscience, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-22	CI
Meridian Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022	22-11-22	CI

Chart Meridian Bioscience, Inc.

Duration

Period

More charts

Company Profile

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution